期刊文献+

SPK1通过调节Bcl-2/Bax途径干扰LLC细胞凋亡 被引量:5

SPK1 interferes with LLC cell apoptosis by regulating Bcl-2/Bax pathway
下载PDF
导出
摘要 目的:研究鞘氨醇激酶1(SPK1)是否通过调节Bcl-2/Bax途径干扰小鼠Lewis肺癌(LLC)细胞的凋亡。方法:通过构建SPK1基因小干扰RNA(siRNA)真核表达载体,将siRNA转染至LLC细胞,在荧光显微镜下观察LLC细胞转染的情况。采用流式细胞术检测转染后LLC细胞的凋亡率,Western blot法检测转染后LLC细胞中SPK1、Bcl-2和Bax蛋白表达水平,ELISA法检测Bax和Bcl-2的蛋白表达。结果:转染后的LLC细胞在荧光显微镜下发出绿色荧光。siRNA-SPK1组细胞凋亡明显高于siRNA-SPK1-Neg组(P<0.01)。Western blot结果显示, siRNA-SPK1组中Bax蛋白表达明显较siRNA-SPK1-Neg组高,Bcl-2蛋白表达较siRNA-SPK1-Neg组低。ELISA结果显示siRNA-SPK1组中Bax表达水平显著高于siRNA-SPK1-Neg组(P<0.01), siRNA-SPK1组中Bcl-2表达水平显著低于siRNA-SPK1-Neg组(P<0.01)。结论:SPK1在LLC细胞中的表达与细胞凋亡率有关。SPK1可能是通过Bcl-2/Bax途径干扰LLC细胞凋亡。 AIM:To investigate whether sphingosine kinase 1(SPK1)interferes with apoptosis of Lewis lung cancer(LLC)cells by regulating the Bcl-2/Bax pathway.METHODS:The SPK1 gene siRNA eukaryotic expression vector was constructed,and transfected into the LLC cells.The transfected LLC cells was observed under a fluorescence microscope.The apoptotic rate of LLC cells after transfection was analyzed by flow cytometry.The expression levels of SPK1,Bcl-2 and Bax in LLC cells after transfection were detected by Western blot.The protein levels of Bax and Bcl-2 were measured by ELISA.RESULTS:Transfected LLC cells emitted green fluorescence under a fluorescence microscope.Apoptosis in siRNA-SPK1 group was significantly higher than that in siRNA-SPK1-Neg group(P<0.01).Western blot analysis showed that the expression of Bax in siRNA-SPK1 group was significantly higher than that in siRNA-SPK1-Neg group,and the expression of Bcl-2 was lower than that in siRNA-SPK1-Neg group.The ELISA results showed that the protein level of Bax in siRNA-SPK1 group was significantly higher than that in siRNA-SPK1-Neg group(P<0.01),and the protein level of Bcl-2 in siRNA-SPK1 group was significantly lower than that in siRNA-SPK1-Neg group(P<0.01).CONCLUSION:The expression of SPK1 in LLC cells is related to the apoptotic rate.SPK1 may interfere with the apoptosis of LLC cells via Bcl-2/Bax pathway.
作者 吕冰洁 赵洁 郝东 王晓芝 王涛 李洪波 杨阳 LV Bing-jie;ZHAO Jie;HAO Dong;WANG Xiao-zhi;WANG Tao;LI Hong-bo;YANG Yang(Department of Respiratory and Critical Care Medicine,Affiliated Hospital of Binzhou Medical College,Binzhou 256603,China;Department of Geriatrics,Affiliated Hospital of Binzhou Medical College,Binzhou 256603,China)
出处 《中国病理生理杂志》 CAS CSCD 北大核心 2019年第5期950-954,960,共6页 Chinese Journal of Pathophysiology
基金 山东省高等学校科技计划项目(No.J17KB080)
关键词 鞘氨醇激酶1 Bcl-2/Bax通路 非小细胞肺癌 细胞凋亡 Sphingosine kinase 1 Bcl-2/Bax pathway Non-small-cell lung cancer Apoptosis
  • 相关文献

参考文献6

二级参考文献26

  • 1李晓博,牟忠卿,陈丽,付艺凌,张岩,咸玉欣,侯新国.糖尿病大鼠肾脏组织氧化应激及其在糖尿病肾病发病中的意义[J].中国病理生理杂志,2006,22(4):806-809. 被引量:24
  • 2Activity and safety of crizotinib in patients with ALK -positive non-small-cell lung cancer: updated results from a phase 1 study[J]. Lancet Oncology . 2012 (10)
  • 3EL Kwak,YJ Bang,DR Camidge,AT Shaw,B Solomon,RG Maki,SH Ou,BJ Dezube,PA Ja?nne,DB Costa,M Varella-Garcia,WH Kim,TJ Lynch,P Fidias,H Stubbs,JA Engelman,LV Sequist,W Tan,L Gandhi,M Mino-Kenudson,GC Wei,SM Shreeve,MJ Ratain,J Settleman.Anaplastic lymphoma kinase inhibition in non-small-cell lung cancer. The New England Quarterly . 2010
  • 4Chen Mao,Li-Xin Qiu,Ru-Yan Liao,Fang-Bing Du,Hong Ding,Wan-Chun Yang,Jin Li,Qing Chen.??KRAS mutations and resistance to EGFR-TKIs treatment in patients with non-small cell lung cancer: A meta-analysis of 22 studies(J)Lung Cancer . 2009 (3)
  • 5JacquesFerlay,Hai‐RimShin,FreddieBray,DavidForman,ColinMathers,Donald MaxwellParkin.??Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008(J)Int. J. Cancer . 2010 (12)
  • 6Shaw AT,Kim DW,Nakagawa K,et al.Crizotinib versus chemo-therapy in advanced ALK-positive lung cancer. The New England Journal of Medicine . 2013
  • 7Mok Tony,Kim DW,Wu YL,et al.First-line crizotinib versus pemetrexedcisplatin or pemetrexed-carboplatin in patients with advanced ALK-positive non-squamous non-small cell lung cancer (NSCLC):results of a phase III study (PROFILE 1014). Journal of Clinical Oncology . 2014
  • 8Sai Hong Ignatius Ou.Efficacy and safety of the ALK inhibitor alectinib in ALK+non-small-cell lung cancer (NSCLC)patients who have failed prior crizotinib:An open-label,singlearm,global phase 2 study (NP28673). ASCO Annual Meeting Abstract . 2015
  • 9Gautschi,Francisco Aya.Clinical outcomes in BRAFV600-mutant metastatic melanoma with sequential treatment with immunotherapy and BRAF inhibitors or vice versa. ASCO Annual Meeting Abstract . 2015
  • 10Pasi A J?nne,Alice T Shaw,José Rodrigues Pereira,Ga?lle Jeannin,Johan Vansteenkiste,Carlos Barrios,Fabio Andre Franke,Lynda Grinsted,Victoria Zazulina,Paul Smith,Ian Smith,Lucio Crinò.??Selumetinib plus docetaxel for KRAS -mutant advanced non-small-cell lung cancer: a randomised, multicentre, placebo-controlled, phase 2 study(J)Lancet Oncology . 2013 (1)

共引文献124

同被引文献61

引证文献5

二级引证文献1

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部